CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update.
Executed a U.S. commercialization agreement with Sandoz for POSIMIR®, including a $20 million upfront payment, as well as milestone payments and double digit royalties.
Total revenues were $4.3 million and net loss was $9.9 million for the three months ended June 30, 2017 as compared to total revenues of $3.2 million and net loss of $9.0 million for the three months ended June 30, 2016.
Executed a U.S. commercialization agreement with Sandoz for POSIMIR®, including a $20 million upfront payment, as well as milestone payments and double digit royalties.
Total revenues were $4.3 million and net loss was $9.9 million for the three months ended June 30, 2017 as compared to total revenues of $3.2 million and net loss of $9.0 million for the three months ended June 30, 2016.
